Nuvalent (NASDAQ: NUVL)
$68.64
(-0.9%)
-$0.61
Price as of May 7, 2024, 4:00 p.m. ET
Nuvalent Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Nuvalent Company Info
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew Shair in January 2017 and is headquartered in Cambridge, MA.
News & Analysis
Featured Article
Why Nuvalent Stock Tanked on Tuesday
The dilution monster stalked the company following the announcement of a new capital-raising effort.
Eric Volkman | Oct 17, 2023
Featured Article
Why Nuvalent Stock Skyrocketed 35% This Week
Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.
Steve Symington | Oct 5, 2023
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.